#1
|
|||
|
|||
Âûðóáàþñü äíåì, äàæå ïðè õîäüáå.
Äîáðûé äåíü! Ìíå 34 ãîäà. Íà÷àëîñü ýòî 6 ëåò íàçàä. ß ðàáîòàë ïî 12 - 14 ÷. â äåíü. Íà ñîí ïðèõîäèëîñü 5- 6 ÷àñîâ, ïðèçíàêîâ ñîíëèâîñòè è êàêèõ ëèáî èçìåíåíèé íå íàáëþäàëîñü, áûëà õîðîøàÿ ðàáîòîñïîñîáíîñòü. Ïîòîì âîçíèêëî ÷óâñòâî ïîñòîÿííãî õîòåíèÿ ñïàòü. Èñïîëüçîâàë ëþáóþ âîçìîæíîñòü ïîñïàòü äíåì ïî íåñêîëüêî ìèíóò, ïðè÷åì òàêàÿ âîçìîæíîñòü âîçíèêàëà â îïðåäåëåííîå âðåìÿ è äëèëàñü ïî 30 ìèí., â òå÷. 2 ëåò. Ïðè íî÷íîì ñíå 5 ÷. è äíåâí. ïî 20 ìèí., ñîìî÷óâñòâèå áûëî íîðìàëüíîå. Ïðè îòñ. äíåâíîãî ñíà ïî÷óâñòâîâàë â íåóäåðæèìîå æåëàíèå óñíóòü â ïðèâû÷íîå âðåìÿ, ïðè÷åì åñëè íå óäàâàëîñü, òî íàñòóïàëî ñîñòîÿíèå "çàòîðìîæåííîãî ÷åëîâåêà". Ñòàë çàìå÷àòü î êðàòêîâðåìååííîì çàñûïàíèè çà ðóëåì à/ì, ïðè äëèòåëüíîé ïåçäêå è ñîíëèâîñòü â ïîñëå îáåäåííîå âðåìÿ. Äàëåå ïîÿâèëîñü ñòðàííîå ÷óâñòâî, ïðè ïîëîæèòåëüíûõ ýìîöèÿõ (ñìåõå), êðàòêîâðåìåííîå (äîëè ñåêóíäû) ðàññëàáëåíèå ìûøö è íåïðåîäîëèìàÿ öèêëè÷íàÿ ñîíëèâîñòü â äíåâíîå âðåìÿ(÷åðåç 6 ÷), íåçàâèñèìî îò ïðåìà ïèùè è ïðè ëþáûõ îáñòîÿòåëüñòâàõ. Èç-çà ÷åãî ðàçâèâàåòñÿ êîìïëåêñ, ñîñòîÿíèå ïîäàâëåííîñòè, ïîñòîÿííîå íåðâíîå íàïðÿæåíèå, äèïðåññèÿ. Óõóäøèëñÿ íî÷íîé ñîí(ïðîáóæäåíèå êàæäûå äâà ÷àñà) èëè äðåìîòà â òå÷åíèè íî÷è, ïîñòîÿííîå âèäèíèå ñíîâ. Óòðîì ñîñòîÿíèå ðàçáèòîñòè è ïîòåðÿííîñòè. Ïðîáûâàë ïðèìåíÿòü óñïîêîèòåëüíûå íàñòîè òðàâ, íåïîìîãëî. Ñíàòâîðíûì íå ïîëüçóþñü, çíàþ ÷òî ìîæíî êðåêî ïðèñåñòü è åùå áîëüøå íàâðåäèòü. Ñî âðåìåíåì ñèìïòîìû ïðîãðåññèðóþò.
Ïîäñêàæèòå ïîæàëóéñòà, êàê æèòü ïîëíîöåííî ïðè òàêèõ ñèìïòîìàõ? Ñóùåñòâóåò êàêàÿ ëèáî ìåòîäèêà ëå÷åíèÿ? |
#2
|
||||
|
||||
Ìàññà òåëà , ðîñò ? ÒÒÃ êðîâè ?
__________________
Ã.À. Ìåëüíè÷åíêî |
#3
|
|||
|
|||
Ìîé ðîñò176, âåñ 80 êã.
Ïîÿñíèòå, ÷òî òàêîå ÒÒÃ? |
#4
|
||||
|
||||
Ïðè÷èíîé ãèïåðñîìíèè ( ïîâûøåííîé ñîíëèâîñòè ) áûâàþò íåêîòîðûå ôîðìû îæèðåíèÿ ( ìû âûÿñíèëè , ÷òî ê ÂÀÌ ýòî íå îòíîñèòñÿ ) è èçðåäêà ãèïîôóíêöèÿ ùèòîâèäíîé æåëåçû . Äëÿ åå èñêëþ÷åíèÿ èññëåäóþò ÒÒà ( òèðåîòðîïíûé ) ãîðìîí . Åñëè ýòîò ïîêàçàòåëü íîðìàëåí , òî ýíäîêðèíîëîã ìîæåò èñêëþ÷èòü ñâîè ïðè÷èíû ÂÀøåãî ñîñòîÿíèÿ.
__________________
Ã.À. Ìåëüíè÷åíêî |
#5
|
|||
|
|||
SlavaArac
À óâåëè÷èòü âðåìÿ íî÷íîãî ñíà íå ïðîáîâàëè? |
#6
|
|||
|
|||
Óâåëè÷åíèå íî÷íîãî ñíà ïðàêòè÷åñêè íå ïîëó÷àåòñÿ, ïî ïðè÷èíå ïîñòîÿííîãî ïðîáóæäåíèÿ â òå÷åíèè íî÷è, ïðèìåðíî ÷åðåç êàæäûå äâà ÷àñà è íà óòðî ñîñòîÿíèå òî÷íî òàêîå æå èëè äàæå õóæå, ÷åì ïðè îáû÷íîì âðåìåíè íà ñîí. Íî åñëè óäàåòñÿ â òå÷åíèè äíÿ ïîñïàòü õîòÿ áû 1 ÷àñ, òî ðàáîòîñïîñîáíîñòü âîññòàíàâëèâàåòñÿ, íî òàêîå óäàåòñÿ íå ÷àñòî.
|
#7
|
|||
|
|||
Î÷åíü ïîõîæå íà "ñòàðûé óòîìëåííûé ìîçã" Ë.Âàíüå. Ïîðîáóéòå ïðèíÿòü îäíîêðàòíóþ äîçó Hyosciamus niger 30 è ïîíàáëþäàòü çà èçìåíåíèåì ñîñòîÿíèÿ.
Ïðåäóïðåæäåíèå: Åñëè îòìåòèòå ïðîÿâëåíèå ñêëîííîñòè ê ýêñãèáèöèîíèçìó (ðåäêî, íî áûâàåò), òî ïåéòå â òå÷åíèè 1=3 äíåé ÷åðíûé êîôå, êîòîðûé ïîñëóæèò àíòèäîòîì ëåêàðñòâà. |
#8
|
|||
|
|||
SlavaArac,
Ïîïðîáóéòå çà ïîë÷àñà ïåðåä òåì êàê ëîæèòüñÿ ïîðàáîòàòü ñ ãàíòåëÿìè ìèíóò íà 10-15. òîëüêî íå æàëóéòåñü îïÿòü íà îòñóòñòâèå âðåìåíè. 10-15 ìèíóò - îá ýòîì ñìåøíî äàæå ãîâîðèòü. È íå ñòàðàéòåñü çàñíóòü, à ïðîñòî ëåæèòå è ðàññëàáëÿéòåñü. Õîòü öåëóþ íî÷ü. Ãëàâíîå ýòî íå ñîí, à ïîëíîå ðàññëàáëåíèå. |
#9
|
|||
|
|||
Óâàæàåìûé SlavaArac!
Âàøå ñîñòîÿíèå õàðàêòåðíî äëÿ íàðêîëåïñèè (íåâðîëîãè÷åñêîå çàáîëåâàíèå, êîòîðîå ïðîÿâëÿåòñÿ íåïðåîäîëèìîé ñîíëèâîñòüþ) ñ ïðèñòóïàìè êàòàïëåêñèè (âíåçàïíûå ïðèñòóïû ïîëíîãî èëè ÷àñòè÷íîãî ìûøå÷íîãî ïàðàëè÷à, îáû÷íî ñâÿçàííûå ñ ñèëüíûì ýìîöèîíàëüíûì âîçáóæäåíèåì). Ñâÿæèòåñü ñ çàâ. ê.ì.í. Áóçóíîâûì Ðîìàíîì Âÿ÷åñëàâîâè÷åì ïî òåë. (095)418-69-07 . Ìû Âàì ïîäñêàæåì èíôîðìàöèþ î ñïåöèàëèñòàõ êîòîðûå çàíèìàþòñÿ ýòîé ïðîáëåìîé. |
#10
|
|||
|
|||
Óâàæàåìàÿ Ñâåòëàíà Áåëîâà!
Áîëüøîå ñïàñèáî çà âàø îòçûâ. Ó ìåíÿ ê Âàì äâà âîïðîñà: 1- Ëå÷èòñÿ ëè Íàðêîëåïñèÿ? è â êàêèõ óñëîâèÿõ? 2- Ìîãóò âîçíèêàòü âûøå èçëîæåííûå ñèìïòîìû ïðè çàòðóäíèòåëüíîì äûõàíèè âî âðåìÿ ñíà(íî÷üþ çàêëàäûâàåò íîñ)? Ñ óâàæåíèåì SlavaArac |
#11
|
|||
|
|||
âîññòàíîâëåíèå íîðìàëüíîãî ðèòìà ñíà
Ñëàâà, çäðàâñòâóéòå! Âñå íà÷àëîñü ñ ðàáîòû ïî 12-14 ÷àñîâ. Åùå îäèí âàæíûé ìîìåíò: â êàêîå âðåìÿ Âû ëîæèëèñü ñïàòü. Ðàáîòà íàøèõ âíóòðåííèõ áèîëîãè÷åñêèõ ÷àñîâ ñâÿçàíà ñ âûðàáîòêîé ãèïîôèçîì îñîáîãî ãîðìîíà - ìåëàòîíèíà, êîòîðûé ïðîäóöèðóåòñÿ â âå÷åðíèå è íî÷íûå ÷àñû. Ìåëàòîíèí âûçûâàåò ðàçâèòèå ïðîöåññîâ òîðìîæåíèÿ â öåíòðàëüíîé íåðâíîé ñèñòåìå. Èìåííî â ñëó÷àå íåäîñòàòêà ïðîäóêöèè ìåëàòîíèíà ïðîèñõîäèò íàðóøåíèå ïðîöåññîâ ñíà. Âîññòàíîâëåíèå íîðìàëüíîãî ðèòìà ñíà ïîìîæåò Âàì èçáåæàòü â áóäóùåì íåâðîçîâ, ãèïåðòîíè÷åñêîé áîëåçíè, ñåðäå÷íîé ïàòîëîãèè è äðóãèõ íåïðèÿòíîñòåé.
Ðîññèéñêèé ïðåïàðàò Ãóä Íàéò, èìåþùèé â ñîñòàâå ìåëàòîíèí, ïîìîæåò Âàì âîññòàíîâèòü ïðîöåññ çàñûïàíèÿ è êà÷åñòâî ñíà. Êðîìå ìåëàòîíèíà ïðåïàðàò ñîäåðæèò ýêñòðàêòû òðàâ, õîðîøî çàðåêîìåíäîâàâøèõ ñåáÿ â ìåäèöèíñêîé ïðàêòèêå: õìåëü (øèøêè), ñòðàñòîöâåò, ðîìàøêà (öâåòêè), øëåìíèê, âàëåðèàíà, êàâà (êîðåíü), ìÿòà ïåðå÷íàÿ. Óäà÷è! |
#12
|
||||
|
||||
Óâàæàåìûé Ñëàâà!
Âàøå îïèñàíèå ñîíëèâîñòè ñ çàëîæåííîñòüþ íîñà î÷åíü ïîõîæå íà "îáñòðóêòèâíîå àïíîý âî âðåìÿ ñíà" - ïðèìåðíî òàê ìîæíî ïåðåâåñòè "obstructive sleep apnea" (ÎSÀ). Âîò êàê åãî îïèñûâàþò â íåäàâíèõ ïóáëèêàöèÿõ: Clin Chest Med. 2003 Jun;24(2):307-13, vii. Indications for treatment of obstructive sleep apnea in adults. Strollo PJ Jr. Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh School of Medicine, University of Pittsburgh Medical Center, Montefiore Hospital, Suite 628 West, 3459 Fifth Avenue, Pittsburgh, PA 15213-2582, USA. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Obstructive sleep apnea is associated with significant daytime sleepiness, reduced quality of life, insulin resistance, motor vehicle crashes, vascular morbidity and mortality. Current evidence supports the belief that all these parameters can be impacted favorably by treatment. Medical therapy with positive pressure eliminates snoring and favorably affects daytime sleepiness, driving risk, vascular function, vascular risk, and quality of life. Treatment may be difficult to accept or adhere to, and some treatment options are not uniformly effective. The long-term impact of treatment is uncertain. Ñðåäè íàèáîëåå ÷àñòî èñïîëüçóåìûõ ìåòîäîâ ëå÷åíèÿ ïðèìåíÿþòñÿ ñëåäóþùèå: 1. Ïðèìåíåíèå ñïåö. àïïàðàòîâ, ñîçäàþùèõ ïðîäîëæèòåëüíîå ïîëîæèòåëüíîå äàâëåíèå â âîçäóõîâûâîäÿùèõ ïóòÿõ; 2. õèðóðãè÷åñêèå âìåøàòåëüñòâà: óâóëîïàëàòîôàðèíãîïëàñòèêà, òðàõåîñòîìèÿ, íîñîâûå îïåðàöèè è äð.; 3. ôàðìàêîòåðàïèÿ: ïðîòðèïòèëèí, ìîäàôèíèë; 4. êèñëîðîäîòåðàïèÿ; 5. ñíèæåíèå ìàññû òåëà; 6. èçìåíåíèå ïîâåäåí÷åñêèõ ïðèñòðàñòèé: ôèçè÷åñêèå òðåíèðîâêè, îòêàç îò àëêîãîëÿ; 7. íîñîâûå äèëàòàòîðû. ß áû Âàì íàñòîÿòåëüíî ðåêîìåíäîâàë ïðîâåðèòü ñâîè àðòåðèàëüíîå äàâëåíèå, òîëåðàíòíîñòü ê ãëþêîçå è ëèïèäû êðîâè. Diabetic Medicine Volume 20 Issue 1 Page 81 - January 2003 Is the severity of obstructive sleep apnoea associated with the degree of insulin resistance? Y. Nagai, Y. Nakatsumi , T. Abe, G. Nomura |
#13
|
|||
|
|||
Òàìàðà, çäðàâñòâóéòå! Ñïàñèáî çà äîáðûé ñîâåò.
Ñëàâà |